Pharming Group N.V. develops and commercializes medicines for rare and ultra-rare diseases, with news focused on RUCONEST®, Joenja® (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, and the company's rare-disease pipeline. Updates commonly cover clinical studies, market authorizations, commercial launches, licensing economics, product revenue trends, and management presentations at healthcare investor conferences.
The company operates as a global biopharmaceutical issuer listed on Euronext Amsterdam and Nasdaq. Recurring coverage also includes financial results, regulatory interactions in major markets, and development programs involving small molecules, biologics, protein replacement therapies, and precision medicines for immunological and genetic conditions.
Pharming Group reported a 35% increase in Q2 2024 revenues to US$74.1 million, driven by strong sales of RUCONEST® and Joenja®. RUCONEST® revenues rose 23% to US$63 million, while Joenja® increased 16% to US$11.1 million from Q1 2024. First half 2024 revenues reached US$129.7 million, up 33% from 1H 2023. The company is on track to meet its 2024 revenue guidance of US$280 million - US$295 million.
However, cash and marketable securities dropped to US$161.8 million due to convertible bond refinancing. Pharming's operating loss narrowed, but net loss was US$1.2 million in Q2 2024, down from a US$1.3 million profit in Q2 2023. The company continues to expand Joenja® availability and expects a decision from the UK MHRA in Q4 2024.
Pharming Group N.V. (Nasdaq: PHAR) has announced it will report its preliminary (unaudited) second quarter and first half 2024 financial results on Thursday, August 1, 2024. The report will cover the period ended June 30. The company will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on the same day.
Interested parties can participate in the conference call by registering in advance. Upon registration, dial-in information and a unique PIN will be provided for call access. The company will only take questions from dial-in attendees. Additionally, a live webcast of the presentation will be available for those who prefer to watch online. Both the conference call and webcast require pre-registration through the provided links.
Pharming Group N.V. (Nasdaq: PHAR) announced its participation in three key investor conferences in June 2024. CEO Sijmen de Vries will present at the Jefferies Healthcare Conference in New York on June 5. CMO Anurag Relan will join a panel at the Oppenheimer Novel Targets in Immunology Summit on June 24. Additionally, Pharming will attend the Oppenheimer 2024 Montauk Life Sciences Summit from June 26-28. These events aim to provide investors with insights into the company's progress and future plans. Live webcasts and replays will be available on Pharming's website.
Pharming Group has provided an update on the regulatory review of leniolisib for treating APDS in the EU. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has affirmed the clinical benefit and safety of leniolisib but requested further clarification on manufacturing controls before approval.
Pharming has been granted an extension to January 2026 to fulfill these requirements. Despite the delay, leniolisib has shown positive efficacy and safety in clinical trials, meeting co-primary endpoints and benefiting patients in long-term studies. The drug is already approved in the US since March 2023. Pharming maintains its 2024 revenue guidance.
Pharming Group announced the results of its 2024 Annual General Meeting (AGM) held on May 21, 2024. All proposals were approved by shareholders, including the reappointment of Ms. Barbara Yanni and Mr. Mark Pykett as Non-Executive Directors for four years. The updated Remuneration Policy for the Board was also accepted. Additionally, shareholders authorized the Board to issue shares and/or options and to repurchase shares. Detailed information and a recording of the AGM are available on Pharming's Investor Relations webpage.
Pharming Group (Nasdaq: PHAR) has announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will be held at NASDAQ, New York, on May 20, 2024.
Michael Levitan, VP of Investor Relations and Corporate Communications, will deliver a presentation at 09:30 EDT/15:30 CET. Investors interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their H.C. Wainwright representative.
Pharming Group has announced the early redemption of the remaining €1.9 million in 3.00% convertible bonds due 2025. Originally, €125 million in bonds were issued, but €123.1 million were repurchased by Pharming on 26 April 2024. The remaining bonds will be redeemed on 18 June 2024 at 100% of their principal amount, with accrued interest paid up to the redemption date. Bondholders have until 7 June 2024 to exercise their conversion rights at a price of €2.0028 per ordinary share. As of the latest trading session, Pharming's stock closed at €0.868.
Pharming Group N.V. reported a strong first quarter in 2024 with a 31% revenue increase to US$55.6 million driven by the U.S. launch of Joenja® and RUCONEST® growth. The company is on track to meet its 2024 revenue guidance of US$280-295 million. Pharming is actively finding more APDS patients and expanding leniolisib availability globally. Leniolisib clinical trials for pediatric and additional indications are progressing. The company refinanced convertible bonds to strengthen its financial position.
Summary not available.
Summary not available.